Symbols

ATRA

Atara·NASDAQ

--(--)

Signals Analysis

Bullish signal 3

Bearish signal 1

Stock Price Surged Significantly

High Gross Profit Margin

Revenue Beats Expectation

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About ATRA

Atara Biotherapeutics, Inc.

A pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for solid tumors, hematologic cancers and autoimmune disease

Industry

Biological Technology

Established Date

08/22/2012

Listing Date

10/16/2014

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.atarabio.com

Security Type

Common stock

Office address

1280 Rancho Conejo Blvd, Thousand Oaks, CA 91320

Business

Introduction

Atara Biotherapeutics, Inc., was incorporated in Delaware on August 22, 2012. The company is a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop translational therapies for patients with cancer and autoimmune diseases.

Company Financials

EPS

ATRA has released its 2025 Q4 earnings. EPS was reported at -0.25, versus the expected -0.25, meeting expectations. The chart below visualizes how ATRA has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

ATRA has released its 2025 Q4 earnings report, with revenue of 1.59M, reflecting a YoY change of -95.13%, and net profit of -3.41M, showing a YoY change of 73.17%. The Sankey diagram below clearly presents ATRA's revenue sources and cost distribution.